NANOTEC and GPO to upgrade drug innovation in Thailand

Published: 5-Jul-2011
Media Research & Development

To support projected growth of pharma market in the region

Thailand’s National Nanotechnology Centre (NANOTEC) and the Government Pharmaceutical Organisation (GPO) have signed a strategic research collaboration agreement to focus on drug discovery using nanotechnology.

The partnership will help upgrade the research capabilities of the two Thai agencies and promote national competitiveness, said Soontorn Vorakul, acting managing director for the GPO.

‘The focus of the research collaboration will be in the area of cosmeceutical and drug delivery using nanotechnology,’ he said.

Professor Sirirurg Songsivilai, executive director of NANOTEC, added that the opportunities for nanotechnology in pharmaceutical manufacturing and development are enormous.

‘It is clear that the international pharmaceutical industry has embraced nanotechnology research in their manufacturing. It is essential for the GPO and NANOTEC to join forces and share expertise if we are to keep pace with drug discovery,’ he said.

Thailand will be the eighth largest economy in the Asia Pacific region by 2016, according to the Economist Intelligence Unit (EIU). GDP growth is projected to increase to 7.1% in the same period.

The EIU also projects an annual growth rate of around 0.7% and the population to be the ninth largest in the Asia Pacific region in five years’ time. The elderly population is also rising; Thailand is expected to have the eighth highest proportion in the Asia Pacific region by 2016.

By 2016 it is estimated that Thailand will have the seventh largest pharmaceutical market in the Asia Pacific region.

See more

You may also like

Manufacturing

Exploring Ireland’s thriving life sciences sector

Read more
NSF highlights its pivotal role in one of the world’s leading hubs for pharma and medical device manufacturing

Trending Articles

  1. Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
  2. Bath scientists design peptide "switch" that keeps Parkinson’s protein in its healthy form Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of a protein linked to Parkinson’s disease and related dementias
  3. Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
  4. Kindeva to showcase complex drug delivery expertise at CPHI 2025 Global CDMO highlights sterile injectable, pulmonary, nasal and dermal capabilities
  5. Designing and developing bioconjugates for clinical success Abzena shares new insights and technologies to accelerate safe and effective ADC development

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Manufacturing

Exploring Ireland’s thriving life sciences sector

NSF highlights its pivotal role in one of the world’s leading hubs for pharma and medical device manufacturing
Manufacturing

Intertronics releases white paper on process validation for medical device bonding

The new guidance helps manufacturers cut costs, save time and ensure ISO and FDA compliance by designing out variability and improving process reliability from the start
Regulatory

FDA lifts clinical hold on Neurizon’s NUZ-001 for ALS trial entry

The decision clears the path for NUZ-001 to join the HEALEY ALS Platform Trial later this year, advancing Neurizon’s lead therapy for amyotrophic lateral sclerosis and strengthening its regulatory and development pipeline
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part II)

Part II of this article focuses on defining what “good” looks like in biorepository infrastructure, validation and documentation, providing practical guidance to create resilient, compliant storage solutions that underpin successful oncology research
Research & Development

Daiichi Sankyo launches third global research institute in San Diego

The company expands its international research footprint with a new San Diego institute, strengthening collaborations in one of the world’s leading life-science hubs and advancing its global drug discovery strategy
Media

Elemental Machines featured in Gartner Hype Cycle for Internet of Things 2025

Recognition highlights the company’s role in advancing connected lab technology and delivering operational intelligence for regulated environments
Research & Development

Bath scientists design peptide "switch" that keeps Parkinson’s protein in its healthy form

Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of a protein linked to Parkinson’s disease and related dementias
Subscribe now